Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ASPHFNASDAQ:ATNFWNASDAQ:SXTPWOTCMKTS:TRSBF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASPHFAscentage Pharma Group International$5.83$5.82$5.42▼$6.45N/AN/A500 shsN/AATNFW180 Life Sciences$0.01-1.2%$0.01$0.00▼$0.04N/AN/A95,374 shs4,281 shsSXTPW60 Degrees Pharmaceuticals$0.06+11.5%$0.06$0.01▼$0.10N/AN/A16,697 shs1,800 shsTRSBF3SBio$3.30+1.5%$2.18$2.22▼$3.35N/AN/A902 shs3,044 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASPHFAscentage Pharma Group International0.00%0.00%0.00%0.00%+116.54%ATNFW180 Life Sciences-1.22%-3.57%-13.83%+19.12%-19.80%SXTPW60 Degrees Pharmaceuticals0.00%+11.46%-12.96%+147.37%-19.54%TRSBF3SBio+1.54%+18.19%+26.92%+298.60%+330.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASPHFAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATRSBF3SBioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASPHFAscentage Pharma Group International 0.00N/AN/AN/AATNFW180 Life Sciences 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ATRSBF3SBio 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASPHFAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$665.45KN/AN/AN/AN/AN/ATRSBF3SBioN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASPHFAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ATRSBF3SBioN/AN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASPHFAscentage Pharma Group InternationalN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ATRSBF3SBioN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASPHFAscentage Pharma Group InternationalN/AATNFW180 Life SciencesN/ASXTPW60 Degrees PharmaceuticalsN/ATRSBF3SBioN/AInsider OwnershipCompanyInsider OwnershipASPHFAscentage Pharma Group InternationalN/AATNFW180 Life SciencesN/ASXTPW60 Degrees PharmaceuticalsN/ATRSBF3SBioN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASPHFAscentage Pharma Group International565N/AN/ANot OptionableATNFW180 Life Sciences7N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableTRSBF3SBio5,411N/AN/ANot OptionableASPHF, ATNFW, TRSBF, and SXTPW HeadlinesRecent News About These CompaniesChinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- UpdateMay 20, 2025 | marketwatch.comBiotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With PfizerMay 20, 2025 | marketwatch.comPfizer Licenses 3SBio Cancer Drug for Record $1.2 BillionMay 20, 2025 | msn.comCosmo and 3SBio Announce Signing of License Agreement for Winlevi® in ChinaJuly 28, 2022 | markets.businessinsider.com3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical developmentAugust 26, 2021 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASPHF, ATNFW, TRSBF, and SXTPW Company DescriptionsAscentage Pharma Group International OTCMKTS:ASPHF$5.83 0.00 (0.00%) As of 07/3/2025Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation. It also has APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449, an oral bioavailable inhibitor of FAK, ROS1, and ALK tyrosine kinases; APG-5918, an orally available and selective EED inhibitor; APG-265, a MDM2 protein degrade; and UBX1967/1325. In, addition it engages in medical research and development; venture capital investment; and rental services. The company has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.180 Life Sciences NASDAQ:ATNFW$0.0081 0.00 (-1.22%) As of 07/3/2025 12:44 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.06 +0.01 (+11.46%) As of 07/3/2025 02:20 PM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.3SBio OTCMKTS:TRSBF$3.30 +0.05 (+1.54%) As of 07/3/2025 12:54 PM Eastern3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
